ADC THERAPEUTICS SA
NYSE: ADCT (ADC Therapeutics SA)
Last update: 2 hours ago0.996
-0.05 (-5.11%)
| Previous Close | 1.05 |
| Open | 1.07 |
| Volume | 1,282,520 |
| Avg. Volume (3M) | 1,649,895 |
| Market Cap | 126,720,552 |
| Price / Sales | 1.86 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | -197.64% |
| Operating Margin (TTM) | -123.58% |
| Diluted EPS (TTM) | -1.42 |
| Quarterly Revenue Growth (YOY) | 27.60% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | -136.07 M |
| Levered Free Cash Flow (TTM) | -110.34 M |
| Return on Assets (TTM) | -27.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ADC Therapeutics SA | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.70 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.58% |
| % Held by Institutions | 66.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tcg Crossover Management, Llc | 31 Mar 2026 | 11,390,175 |
| Prosight Management, Lp | 31 Mar 2026 | 8,300,000 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AZELBY ROBERT | - | 3.08 | -12,600 | -38,808 |
| BIZZARI JEAN-PIERRE | - | 3.08 | -12,600 | -38,808 |
| COUGHLIN TIMOTHY | - | 3.08 | -12,600 | -38,808 |
| HUG PETER | - | 3.08 | -2,156 | -6,640 |
| MONGES VIVIANE | - | 3.08 | -2,596 | -7,996 |
| SANDOR VICTOR | - | 3.08 | -12,600 | -38,808 |
| SQUARER RON | - | 3.08 | -15,196 | -46,804 |
| Aggregate Net Quantity | -70,348 | |||
| Aggregate Net Value ($) | -216,672 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.08 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COUGHLIN TIMOTHY | Director | 03 Jun 2026 | Disposed (-) | 12,600 | 3.08 | 38,808 |
| BIZZARI JEAN-PIERRE | Director | 03 Jun 2026 | Disposed (-) | 12,600 | 3.08 | 38,808 |
| HUG PETER | Director | 03 Jun 2026 | Disposed (-) | 2,156 | 3.08 | 6,640 |
| MONGES VIVIANE | Director | 03 Jun 2026 | Disposed (-) | 2,596 | 3.08 | 7,996 |
| SANDOR VICTOR | Director | 03 Jun 2026 | Disposed (-) | 12,600 | 3.08 | 38,808 |
| SQUARER RON | Director | 03 Jun 2026 | Disposed (-) | 15,196 | 3.08 | 46,804 |
| AZELBY ROBERT | Director | 03 Jun 2026 | Disposed (-) | 12,600 | 3.08 | 38,808 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |